Aptose Biosciences (APS) Competitors

Aptose Biosciences logo
C$0.28 -0.03 (-8.20%)
As of 03:50 PM Eastern

APS vs. CZO, REUN, NEPT, ATE, SBM, KNE, RVX, IMV, IOT, and RVV

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Ceapro (CZO), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), Antibe Therapeutics (ATE), Sirona Biochem (SBM), Kane Biotech (KNE), Resverlogix (RVX), IMV (IMV), Innovotech (IOT), and Revive Therapeutics (RVV). These companies are all part of the "biotechnology" industry.

Aptose Biosciences vs.

Ceapro (CVE:CZO) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.

Aptose Biosciences received 153 more outperform votes than Ceapro when rated by MarketBeat users. Likewise, 72.11% of users gave Aptose Biosciences an outperform vote while only 60.82% of users gave Ceapro an outperform vote.

CompanyUnderperformOutperform
CeaproOutperform Votes
59
60.82%
Underperform Votes
38
39.18%
Aptose BiosciencesOutperform Votes
212
72.11%
Underperform Votes
82
27.89%

15.1% of Aptose Biosciences shares are owned by institutional investors. 4.0% of Ceapro shares are owned by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aptose Biosciences has a net margin of 0.00% compared to Ceapro's net margin of -69.73%. Aptose Biosciences' return on equity of 1,017.48% beat Ceapro's return on equity.

Company Net Margins Return on Equity Return on Assets
Ceapro-69.73% -21.67% -11.30%
Aptose Biosciences N/A 1,017.48%-136.29%

Ceapro has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

In the previous week, Ceapro's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.

Company Overall Sentiment
Ceapro Neutral
Aptose Biosciences Neutral

Ceapro has higher revenue and earnings than Aptose Biosciences. Ceapro is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$348.52K1.98-C$243.04K-C$0.08-2.83
Aptose BiosciencesN/AN/A-C$154.69M-C$5.02-0.06

Summary

Aptose Biosciences beats Ceapro on 7 of the 12 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APS vs. The Competition

MetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$12.06MC$113.50MC$5.81BC$5.78B
Dividend Yield0.39%3.78%5.29%6.47%
P/E Ratio-0.063.2326.0731.25
Price / SalesN/A5,113.70459.52472.03
Price / Cash1.6012.7546.0982.16
Price / Book-0.3149.647.413.94
Net Income-C$154.69M-C$90.50MC$3.19BC$296.42M
7 Day Performance3.70%1.13%-0.23%1.68%
1 Month Performance-9.68%10.56%6.21%5.48%
1 Year Performance-89.67%106.19%26.11%46.17%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APS
Aptose Biosciences
N/AC$0.28
-8.2%
N/A-89.0%C$12.06MN/A-0.0631Gap Down
CZO
Ceapro
N/AC$0.23
-11.8%
N/A+32.4%C$17.62MC$9.63M-3.75N/AGap Down
REUN
Reunion Neuroscience
N/AN/AN/AN/AC$16.64MC$4.86M-0.43190Gap Down
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AC$15.73MC$48.80M-0.08130Gap Down
ATE
Antibe Therapeutics
N/AN/AN/AN/AC$15.64MC$9.71M-0.8411
SBM
Sirona Biochem
N/AC$0.06
+20.0%
N/A-22.2%C$15.41MC$683,768.00-6.00N/AGap Up
KNE
Kane Biotech
N/AC$0.11
+4.8%
N/A+37.5%C$14.58MC$2.74M-3.67N/A
RVX
Resverlogix
N/AC$0.05
-9.1%
N/A-23.1%C$13.85MN/A-1.0019Gap Down
IMV
IMV
N/AN/AN/AN/AC$13.12MC$23,000.00-0.1820
IOT
Innovotech
N/AC$0.19
+5.6%
N/A+126.3%C$7.41MC$1.23M-19.001,620Gap Up
RVV
Revive Therapeutics
N/AC$0.08
+14.3%
N/A+0.0%C$5.79MN/A-3.64N/AGap Up
High Trading Volume

Related Companies and Tools


This page (TSE:APS) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners